All of the statements about exenatide are true except (AIIMS May 2010)
|A||It is a GLP -1 analogue|
|B||It can be used for treatment of Type 1 diabetes mellitus|
|C||It is given subcutaneously|
|D||It decreases glucagons|
a. Exenatide is a GLP-1 receptor agonist that is more resistant to DPP-4 action and cleared by the kidney.
b. When this drug is given to patients with type 2 diabetes by subcutaneous injection twice daily, it lowers blood
c. Glucose and HbA1c levels. It is not indicated in type 1 diabetes.
d. Exenatide appears to have the same effects as GLP-1 on glucagon suppression and gastric emptying.